Skip to main content
Professional Technical IVT

myelodysplastic syndrome

Also written as: MDS — myelodysplastic syndrome

A group of clonal hematopoietic disorders characterized by dysplastic changes in bone marrow cells and peripheral blood cytopenias.

Full Definition

Myelodysplastic syndrome (MDS) refers to a heterogeneous group of clonal hematopoietic stem cell disorders characterized by dysplastic cellular morphology in bone marrow and peripheral blood, along with cytopenias despite normal or increased cellularity in the bone marrow. These disorders represent a spectrum of diseases that may progress to acute myeloid leukemia. MDS primarily affects older adults and is often secondary to prior chemotherapy or radiation exposure. The condition is diagnosed through bone marrow examination showing dysplastic changes and specific cytogenetic abnormalities.

Usage

Usage note: Often abbreviated as MDS in clinical contexts. Avoid the outdated term 'preleukemia' in formal documentation.

In Context

  • "The patient's bone marrow biopsy revealed dysplastic changes consistent with myelodysplastic syndrome." — Pathology report
  • "Treatment options for high-risk myelodysplastic syndrome include hypomethylating agents and allogeneic stem cell transplantation." — Treatment protocol

Also known as

MDS preleukemia

Don't confuse with

myelofibrosis aplastic anemia

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON